80366-57-0

Upstream product

• 6261-84-3 propan-2-one O-2-morpholinoethyl oxime 
• 98883-94-4 benzophenone O-(2-morpholin-4-yl-ethyl)-oxime 
• 3240-94-6 N-(2-chlorethyl)morpholine 
• 3647-69-6 4-(2-chloroethyl)morpholine hydrochride 
• 606143-97-9 (2-Morpholin-4-yl-ethoxy)-carbamic acid tert-butyl ester 
• 622-40-2 2-(morpholin-4-yl)ethanol 

Downstream Products

• 61819-94-1 4-isopropyl-benzaldehyde O-(2-morpholin-4-yl-ethyl)-oxime 
• 6261-96-7 1-(4-ethoxy-phenyl)-3-(2-morpholin-4-yl-ethoxy)-thiourea 
• 33440-38-9 4-phenyl-but-3-en-2-one O-(2-morpholin-4-yl-ethyl)-oxime 
• 112772-28-8 2,6-Dimethyl-5-{1-[(E)-2-morpholin-4-yl-ethoxyimino]-ethyl}-4-(3-nitro-phenyl)-1,4-dihydro-pyridine-3-carboxylic acid methyl ester 
• 785725-31-7 (2,3-Dichloro-4-methoxy)-phenyl 2-thienyl O-(morpholinoethyl)-ketone oxime 
• 1310569-96-0 (E)-1-(4-(7-methoxyfuro[2,3-b]quinolin-4-ylamino)phenyl)ethanone O-2-morpholinoethyl oxime 
• 1310570-04-7 (E)-1-(4-(3-chloro-7-methoxyfuro[2,3-b]quinolin-4-ylamino)phenyl)ethanone O-2-morpholinoethyl oxime 
• 1310569-80-2 (E)-1-(4-(furo[2,3-b]quinolin-4-ylamino)phenyl)ethanone O-2-morpholinoethyl oxime 
• 1310569-88-0 (E)-1-(4-(3-chlorofuro[2,3-b]quinolin-4-ylamino) phenyl)ethanone O-2-morpholinoethyl oxime 
• 944341-54-2 JNJ-28871063 

Relevant academic research and scientific papers

HYDROXAMATE COMPOUNDS AS ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR

The present invention relates to compounds of formula I shown below: (I) wherein R1, R2 and R3 are each as defined in the application. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or conditions in which adenosine A2a receptor activity is implicated, such as, for example, cancer.

Psoromic acid is a selective and covalent rab-prenylation inhibitor targeting autoinhibited rabggtase

Post-translational attachment of geranylgeranyl isoprenoids to Rab GTPases, the key organizers of intracellular vesicular transport, is essential for their function. Rab geranylgeranyl transferase (RabGGTase) is responsible for prenylation of Rab proteins

THIAZOLYL-DIHYDRO-INDAZOLES

The present invention encompasses compounds of general formula (1) wherein R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a

MODULATORS OF HYPOXIA INDUCIBLE FACTOR-1 AND RELATED USES

The invention features compounds of formula (I): and pharmaceutically acceptable salts and prodrugs thereof, as well methods for modulating the effects of local and systemic hypoxic events using the compounds.

FUSED HETEROCYCLIC COMPOUND

A compound of the formula: wherein ring'' A is a 7-membered or 8-membered nitrogen- containing ring optionally further substituted, ring B is an optionally substituted aryl group or an optionally substituted heteroaryl group, X1 is a group represented by -NR3-Y1-, -0-, -S-, -SO-, -SO2- or -CHR3- wherein R3 is a hydrogen atom or'' an optionally substituted aliphatic hydrocarbon group, or R3 may be bonded to the carbon atom of ring B to form an optionally substituted ring structure, and Y1 is a bond or an optionally substituted C1-4 alkylene, R1 is a hydrogen atom, or an optionally substituted group bonded via a carbon atom or a sulfur atom, the formula = shows a single bond or a double bond, when ===R2 is - R2, R2 is a hydrogen atom, or an optionally substituted group bonded via a carbon atom, a nitrogen atom, an oxygen atom or a sulfur atom, and when ===R2 is =R2, R2 is an oxo group, an optionally substituted alkylidene group, or an optionally, substituted imino group.

4-Amino-6-piperazin-1-yl-pyrimidine-5-carbaldehyde oximes as potent FLT-3 inhibitors

A series of 4-amino-6-piperazin-1-yl-pyrimidine-5-carbaldehyde oximes has been discovered and developed as potent FLT3 tyrosine kinase inhibitors. The series exhibited potent antiproliferative activity against both an FLT3 ITD-mutated human leukemic cell line as well as a wild-type FLT3 BaF3 expressed cell line. The structure-activity relationship of this class of compounds is described.

SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOPYRIMIDINES KINASE MODULATORS

The invention is directed to a method of inhibiting FLT3 tyrosine kinase activity or expression or reducing FLT3 kinase activity or expression in a cell or a subject comprising the administration of a farnesyl transferase inhibitor and a FLT3 kinase inhibitor selected from aminopyrimidine compounds of Formula I′: where R3, B, Z, Q, p, q and R1 are as defined herein. Included within the present invention is both prophylactic and therapeutic methods for treating a subject at risk of (or susceptible to) developing a cell proliferative disorder or a disorder related to FLT3.

SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOPYRIMIDINES KINASE MODULATORS

The invention is directed to a method of inhibiting FLT3 tyrosine kinase activity or expression or reducing FLT3 kinase activity or expression in a cell or a subject comprising the administration of a farnesyl transferase inhibitor and a FLT3 kinase inhibitor selected from aminopyrimidine compounds of Formula I′: where R3, B, Z, r and R1 are as defined herein. Included within the present invention is both prophylactic and therapeutic methods for treating a subject at risk of (or susceptible to) developing a cell proliferative disorder or a disorder related to FLT3.

AMINOPYRIMIDINES AS KINASE MODULATORS

The invention is directed to aminopyrimidine compounds of Formula I: where R3, B, Z, Q, p, q and R1 are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3 and/or c-kit and/or TrkB, the use of such compounds to reduce or inhibit kinase activity of FLT3 and/or c-kit and/or TrkB in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 and/or c-kit and/or TrkB. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

AMINOPYRIMIDINES AS KINASE MODULATORS

Abstract The invention is directed to aminopyrimidine compounds of Formula I: where R3, B, Z, r and R1 are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3 and/or c-kit and/or TrkB, the use of such compounds to reduce or inhibit kinase activity of FLT3 and/or c-kit and/or TrkB in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 and/or c-kit and/or TrkB . The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.